Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is curative for a variety of malignant hematological diseases that are traditionally poorly responsive to standard therapies. Allo-HCT is effective because of the donor vs. host alloimmune responses that occur following transplantation.   These alloimmune responses are driven by donor T cells and are so potent that they can potentially eradicate chemotherapy refractory leukemia [1–3] However, donor T cells can also recognize recipient tissues and mount an immunological attack resulting in graft vs. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 22, 2021 Category: Hematology Authors: Logan G. Spector, Stephen R. Spellman, Bharat Thyagarajan, Kenneth B. Beckman, Cody Hoffmann, John Garbe, Theresa Hahn, Lara Sucheston-Campbell, Michaela Richardson, Todd E. De For, Jakub Tolar, Michael R. Verneris Source Type: research

Upregulation of Nrf-2 attenuates oxidative stress-induced complement activation-associated endothelial injury and apoptosis in transplant-associated thrombotic microangiopathy.
Transplant-associated thrombotic microangiopathy (TA-TMA) is a recognized fatal complication after hematopoietic stem cell transplantation (HSCT). The pathological diagnosis is difficult due to the difficulty in obtaining biopsy samples in post-transplant patients. The TA-TMA incidence reported in previous studies ranges from 0 to 64%, while the mortality rate is as high as 60% to 75%.[1] TA-TMA patients' clinical manifestations include anemia, thrombocytopenia, elevated lactate dehydrogenase (LDH), increased schistocytes in the blood, severe hypertension, and proteinuria. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 22, 2021 Category: Hematology Authors: Rui Zhang, Jiaqian Qi, Meng Zhou, Tingting Pan, Ziyan Zhang, Yifang Yao, Haohao Han, Yue Han Source Type: research

Post-transplant Cyclophosphamide versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for AML and MDS
The ability to identify a fully HLA matched donor for patients requiring allogeneic stem cell transplant (alloSCT) has dramatically improved due mainly to the increase in the unrelated donor registries. As a result, up to 75% of Caucasian patients are able to find a suitable unrelated donor (1, 2). While participation of volunteers in the registry continues to increase, transplant access for other ethnic and racial minorities remains an area of critical need, often times, relying on less than fully matched donors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 22, 2021 Category: Hematology Authors: Dipenkumar Modi, Kyle Kondrat, Seongho Kim, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti Source Type: research

Novel indicators of transplant outcomes for PhALL: “current molecular-relapse-free survival”
Generally, patients with Philadelphia chromosome −positive acute lymphoblastic leukemia (PhALL) are considered to have inferior survival outcomes, and allogeneic hematopoietic cell transplantation (allo-HCT) has been offered to eligible patients.1-3 The introduction of tyrosine kinase inhibitor (TKI) has contributed to the improvement of clinica l outcomes for PhALL. Historically, the combination of chemotherapies and TKI has induced durable molecular remission, and a growing number of PhALL patients have become eligible to receive allo-HCT during their first remission. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 22, 2021 Category: Hematology Authors: Hideki Nakasone, Shinichi Kako, Takayoshi Tachibana, Masatsugu Tanaka, Makoto Onizuka, Satoshi Takahashi, Akira Yokota, Shin-ichiro Fujiwara, Toru Sakura, Emiko Sakaida, Shin Fujisawa, Rie Yamazaki, Moritaka Gotoh, Maki Hagihara, Nobuyuki Aotsuka, Nobuhir Source Type: research

Recognition of Hematopoietic Stem Cell Transplant and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focus Competence in Canada
: Hematopoietic stem cell transplantation (HSCT) and cellular therapy (CT) exploit the therapeutic potential of manipulated or unmanipulated hematopoietic cells to treat diseases. While initially dedicated to the treatment of hematological malignancies and disorders, its efficacy is currently being investigated in several diseases and cancers. Indications are currently booming. In the midst of this expansion, both the American Society for Transplantation and Cellular Therapy (ASTCT) and European Society for Blood and Marrow Transplantation (EBMT) have highlighted the global shortage of hematologists adequately trained in t...
Source: Biology of Blood and Marrow Transplantation - June 18, 2021 Category: Hematology Authors: Sylvie Lachance, Marcio M. Gomes, Nadia M. Bambace, Henrique Bittencourt, Kylie Lepic, Mona Shafey, Jolanta Karpinski, Gregory M.T. Guilcher Tags: Perspective Source Type: research

Reduction in late mortality among patients with Multiple Myeloma treated with Autologous Peripheral Blood Stem Cell Transplantation – a BMTSS Report
The past two decades have witnessed a sizeable improvement in survival among patients with Multiple Myeloma (MM).1 This is particularly true for younger patients ( ≤65y) where 10y survival rates now exceed 35%.2,3 With an increased lifespan, late complications of therapy and their contribution towards late mortality have become more relevant. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 18, 2021 Category: Hematology Authors: Smith Giri, Yanjun Chen, Jessica Wu, Lindsey Hageman, Joshua Richman, Liton Francisco, Wendy Landier, Luciano Costa, Andrew McDonald, Donna Murdaugh, F Lennie Wong, Daniel J. Weisdorf, Stephen J. Forman, Mukta Arora, Saro H. Armenian, Smita Bhatia Source Type: research

Allogenic hematopoietic stem cell transplantation is feasible in pediatric patients with an active or recently diagnosed invasive fungal infection
Allogenic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for a variety of hematologic malignancies as well as a range of nonmalignant disorders. Evolution of transplant management and progress in supportive care including the initiation of antimicrobial prophylaxis has improved survival after allogenic HSCT over the last decades. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 18, 2021 Category: Hematology Authors: Laura G.Y. Rotte, Yvette G.T. Loeffen, Marc B. Bierings, Tom F.W. Wolfs, Caroline A. Lindemans Source Type: research

The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients That Are “Poor Responder” to Induction- The Mayo Clinic Experience
We report the outcomes of 117 newly diagnosed multiple myeloma patients who received novel agents induction, had a poor response to induction and were mobilized using intravenous intermediate-dose cyclophosphamide (82%) or VD-PACE (18%) plus G-CSF and “on-demand” plerixafor. The median PFS and OS of the chemo-mobilized cohort were 21 months (95% CI 15-71) and 58 months (95% CI 47-80), respectively. We compared our cohort to a 117-patient cohort matched by the level of response at pretransplant evaluation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 18, 2021 Category: Hematology Authors: Iuliana Vaxman, Eli Muchtar, Eapen Jacob, Kapoor Prashant, Shaji Kumar, Angela Dispenzieri, Francis Buadi, David Dingli, Wilson Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Martha Lacy, William Hogan, Morie Gertz Source Type: research

Female Sex is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant
We examined the influence of patient sex and donor-recipient sex matching on overall survival in a landmark analysis of long-term survivors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 16, 2021 Category: Hematology Authors: Prioty Islam, Helen Tang, Haesu Jin, Felicia Cao, Lauren M. Bohannon, Yi Ren, Nelson J. Chao, Taewoong Choi, Cristina Gasparetto, Mitchell E. Horwitz, Gwynn D. Long, Richard D. Lopez, David A Rizzieri, Stefanie Sarantopoulos, Anthony D. Sung Source Type: research

Outcomes after haploidentical cell transplantation with posttransplant cyclophosphamide: a systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimen and bone marrow with peripheral blood stem-cell graft: PTCy: PBSC or BM and MAC or RIC for Haplo-HCT with PTCy
Haploidentical hematopoietic cell transplantation (Haplo-HCT) with posttransplant cyclophosphamide (PTCy) is emerging as a new standard in the western world for Haplo-HCT. The procedure is relatively straightforward and easily reproducible1, obviating the need for expensive T-cell depletion techniques and greatly expanding the pool of donors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 16, 2021 Category: Hematology Authors: Leonardo Javier Arcuri, Nelson Hamerschlak, Vanderson Rocha, Carmem Bonfim, Mariana Nassif Kerbauy Source Type: research

Biobehavioral research and hematopoietic stem cell transplantation: Expert review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy
The interactions of behavioral, psychological, and socioenvironmental factors with biological processes (summarized as ‘biobehavioral’) throughout the hematopoietic cell transplantation (HCT) trajectory significantly impact both psychological and physical morbidity and mortality [1, 2]. The adverse effects of stress-related biobehavioral factors (including psychological and socioenvironmental factors) on immune function have already been well documented in cancer populations. The effects are likely to be especially salient in the HCT context given the importance of optimal immune recovery and function in reduci...
Source: Biology of Blood and Marrow Transplantation - June 14, 2021 Category: Hematology Authors: Debra Lynch Kelly, Karen Syrjala, Mallory Taylor, Kelly E. Rentscher, Shahrukh Hashmi, William A. Wood, Heather Jim, Anna Barata, Kathryn E. Flynn, Linda J. Burns, Bronwen E. Shaw, Effie Petersdorf, Anela Carrazana Yero, Amanda D. Emmrich, Keayra E. Morri Source Type: research

Moral distress: its manifestations in healthy donors during peripheral blood hematopoietic stem cell harvesting
In the 1980s, the number of allogeneic hematopoietic stem cell transplantations (allo-HSCTs) performed was low; however, at the end of the 1990s, a sustained increase was observed. In 2016, 8539 cases of allo-HSCT were reported by the Center for International Blood and Marrow Transplant Research (CIBMTR) (1). Many changes have occurred for the benefit of patients receiving an allo-HSCT, such as better antibiotics, antifungals and immunosuppressants. In the area of hematopoietic cell donors, however, there have been few changes throughout this time. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 11, 2021 Category: Hematology Authors: Cesar H. Guti érrez-Aguirre, José C. Jaime-Pérez, Fernando de la Garza-Salazar, Geraldina Guerrero-González, Abel Guzmán-López, Guillermo J. Ruiz-Arguelles, David Gómez-Almaguer, Olga G. Cantú-Rodríguez Source Type: research

Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation: Plasma MMP-9 in BOS
Bronchiolitis obliterans syndrome (BOS) is a highly morbid form of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). BOS also occurs after lung transplantation and is characterized by peribronchial fibrosis and intraluminal obstruction of the small terminal airways, resulting in airflow obstruction.1 At least 3 plasma proteins, matrix metalloproteinase-9 (MMP-9), MMP-3 and chitinase-3-like1 glycoprotein (YKL-40), have been identified as biomarkers for BOS after lung transplantation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 11, 2021 Category: Hematology Authors: Yoshihiro Inamoto, Paul J. Martin, Lynn E. Onstad, Guang-Shing Cheng, Kirsten M. Williams, Iskra Pusic, Vincent T. Ho, Mukta Arora, Joseph Pidala, Mary E.D. Flowers, Ted A. Gooley, Richard L. Lawler, John A. Hansen, Stephanie J. Lee Source Type: research

Full dose Cyclophosphamide with the addition of Fludarabine for Matched Sibling transplants in Severe Aplastic Anemia
Aplastic anemia (AA) is a rare non-neoplastic disease characterized by bone marrow failure as a result of immune-mediated destruction of the hematopoietic stem cells; it is defined as pancytopenia with a hypocellular bone marrow [ (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 11, 2021 Category: Hematology Authors: Riad El Fakih, Saud Alhayli, Syed Osman Ahmed, Marwan Shaheen, Naeem Chaudhri, Fahad Alsharif, Amr Hanbali, Feras Alfraih, Alfadel Alshaibani, Ali Assiri, Hadeel Samarkandi, Fatima Babiker, Ahmad Alshomar, Anas Alhakim, Emad Ghabashi, Ahmed Kotb, Tusneem Source Type: research

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report
Positive results from recent clinical trials have significantly expanded current therapeutic options for patients with chronic graft-versus-host disease (GVHD). However, new insights into the associations between clinical characteristics of chronic GVHD, pathophysiologic mechanisms of disease, and the clinical and biological effects of novel therapeutic agents are required to allow for a more individualized approach to treatment. The current report is focused on setting research priorities and direction in the treatment of chronic GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 10, 2021 Category: Hematology Authors: Zachariah DeFilipp, Daniel R. Couriel, Aleksandr Lazaryan, Vijaya Raj Bhatt, Nataliya P. Buxbaum, Amin M. Alousi, Attilio Olivieri, Drazen Pulanic, Joerg P. Halter, Lori A. Henderson, Robert Zeiser, Ted A. Gooley, Kelli P.A. MacDonald, Daniel Wolff, Kirk Source Type: research

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in part due to non-reversible fibrosis which impacts physical functioning (eye, skin, lung manifestations) and mortality (lung, gastrointestinal manifestations). Progress in preventing severe morbidity and mortality associated with chronic GVHD is limited by a complex and incompletely understood disease biology and a lack of prognostic biomarkers. Likewise, treatment advances for highly morbid manifestations remain hindered by the absence of effective organ-specific approaches targeting “irreversible” fibrotic sequelae and di...
Source: Biology of Blood and Marrow Transplantation - June 10, 2021 Category: Hematology Authors: Daniel Wolff, Vedran Radojcic, Robert Lafyatis, Resat Cinar, Rachel K. Rosenstein, Edward W. Cowen, Guang-Shing Cheng, Ajay Sheshadri, Anne Bergeron, Kirsten M. Williams, Jamie L. Todd, Takanori Teshima, Geoffrey D.E. Cuvelier, Ernst Holler, Shannon R McC Source Type: research

Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.
Allogeneic stem cell transplantation (allo-SCT) is a curative treatment for several hematological malignancies including acute myeloid leukemia (AML). Considerable frequency of post-transplant relapses and non-relapse mortality (NRM) caused by Graft- versus- host diseases (GVHD), organ toxicity, and infectious complications represent limiting factors for success of this approach. Studies evaluating the impact of measurable residual disease (MRD) have been expanding in the last decades and clearly demonstrated higher relapses and lower survival in pre-transplant MRD+ AML patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 9, 2021 Category: Hematology Authors: Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Dietlinde Janson, Francis Ayuk, Christine Wolschke, Ulrike Bacher, Nicolaus Kr öger Source Type: research

Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease (GVHD)
Chronic graft-versus-host disease (cGVHD) remains a major barrier to a successful hematopoietic stem cell transplantation (HSCT); in cases refractory to first-line therapy with steroids, there is no standard of care for second-line therapy. As such, ruxolitinib is a promising drug in this scenario. We retrospectively analyzed its efficacy and safety as treatment of steroid-refractory cGVHD in 35 patients from two transplant centers, with the longest follow-up described to date. Evaluated patients had a median of 3 organs affected (1-7), with most (64%) having moderate cGVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 8, 2021 Category: Hematology Authors: Aliana Meneses Ferreira, Roberta Shcolnik Szor, Vinicius Campos Molla, Maria Cristina Seiwald, Pedro Arruda de Moraes, Ana Rita Brito Medeiros da Fonseca, Erick Menezes Xavier, Mariana Gomes Serpa, Luciana Tucunduva, Yana Novis, Celso Arrais-Rodrigues Source Type: research

Infection related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: An Australian registry report
Allogeneic hematopoietic cell transplantation (HCT) is standard therapy for many hematological malignancies and severe congenital or acquired disorders of the hematopoietic system.1 Whilst improvements in supportive care, patient and donor selection and HCT techniques have increased survival over time, HCT recipients have a high risk of death, with approximately 20-40% 1 year mortality in most patient populations.2-4 The major cause of death is relapse, which accounts for approximately 40% of all deaths, followed by infections at 25% and graft-versus-host disease (GVHD) at 20%. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 7, 2021 Category: Hematology Authors: Julian Lindsay, Ian Kerridge, Leonie Wilcox, Steven Tran, Tracey A. O'Brien, Matthew Greenwood, Sharon C-A Chen, David CM Kong, Steven A. Pergam, Catherine Liu, Monica A. Slavin Source Type: research

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
The objectives of the 2020 workshop included discussing the latest scientific developments in plasma cell disorders (PCDs) with an emphasis on the immunology and molecular biology, presenting the most current clinical trial results with MRD and IP data, understanding regulatory issues regarding the use of novel endpoints in clinical trial design and drug approval, discussing novel strategies for MRD and IP testing and encouraging investigators and trainees from around the world to interact with experts in the field of PCDs. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 6, 2021 Category: Hematology Authors: Sarah A. Holstein, Nizar Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli, Carrie Brownstein, Pierre Demolis, David Foureau, Francesca Gay, Irene M. Ghobrial, Nicole Gormley, Jens Hillengass, Martin Kaiser, Marcela V. Maus, J. Joseph Melenhorst, Source Type: research

Association of inherited chromosomally integrated human herpesvirus 6 with neurologic symptoms and management after allogeneic hematopoietic cell transplantation
Reactivation of human herpesvirus 6 (HHV-6) after allogeneic hematopoietic cell transplant (HCT) is associated with neurologic complications, but the impact of donor and/or recipient inherited chromosomally integrated HHV-6 (iciHHV-6) on post-HCT central nervous system (CNS) symptoms, diagnostic and therapeutic interventions is not well understood. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 6, 2021 Category: Hematology Authors: Madeleine R. Heldman, Cassandra Job, Joyce Maalouf, Jessica Morris, Hu Xie, Chris Davis, Terry Stevens-Ayers, Meei-Li Huang, Keith R. Jerome, Jesse R. Fann, Danielle M. Zerr, Michael Boeckh, Joshua A. Hill Source Type: research

An Open-label, Single-arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease
Chronic GVHD (cGVHD), an immune-mediated syndrome,1 is one of the major life-threatening complications and a leading cause of non-relapse mortality following allo-HSCT.2,3 It leads to severe morbidity, and poor health-related quality of life (HRQoL).4,5 Overall, cGVHD occurs in 30% to 70% of patients after allo-HSCT,5 depending on several factors, including donor and graft source.6 The 2-year cumulative incidence of cGVHD was found to be 35.4% (n  = 145/406) in a prospective, longitudinal study conducted in HSCT patients at Japanese centers per 2005 National Institutes of Health (NIH) Consensus Development Pr...
Source: Biology of Blood and Marrow Transplantation - June 5, 2021 Category: Hematology Authors: Noriko Doki, Masako Toyosaki, Souichi Shiratori, Tomoo Osumi, Masaya Okada, Toshiro Kawakita, Masashi Sawa, Takayuki Ishikawa, Yasunori Ueda, Nozomi Yoshinari, Susumu Nakahara Source Type: research

Methods to assess disease activity and severity in cutaneous chronic graft-versus-host disease: a critical literature review
Graft-vs-host disease (GVHD), a common complication of allogeneic hematopoietic cell transplant (HCT), confers substantial risk for morbidity, mortality and diminished quality of life.1 Typically developing a few months after HCT, chronic GVHD (cGVHD) most frequently involves the skin and mucosal surfaces, although multiple organs may be affected, including the eyes, lungs, liver and GI tract.2,3 Cutaneous cGVHD can be classified clinically as sclerotic or non-sclerotic (Fig 1, 2).3 Although sclerotic cGVHD (ScGVHD) is not acutely life-threatening, widespread involvement may lead to considerable functional disability. (Sou...
Source: Biology of Blood and Marrow Transplantation - June 5, 2021 Category: Hematology Authors: Hadir Shakshouk, Eric R. Tkaczyk, Edward W. Cowen, Rokea A. el ‐Azhary, Shahrukh K. Hashmi, Saad J. Kenderian, Julia S. Lehman Source Type: research

Metabolic syndrome in male survivors of pediatric allogeneic hematopoietic stem cell transplantation: impact of total body irradiation, low-grade inflammation, and hypogonadism
Metabolic syndrome (MetS) is a growing concern in survivors of pediatric hematopoietic stem cell transplantation (HSCT), but little is known about the underlying mechanisms. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 3, 2021 Category: Hematology Authors: Ena Muhic, Sidsel Mathiesen, Malene Mejdahl Nielsen, Anu Suominen, Kaspar S ørensen, Marianne Ifversen, Rúna Louise Nolsöe, Kasper Mønsted Pedersen, Päivi Lähteenmäki, Børge Grønne Nordestgaard, Anders Juul, Kirsi Jahnukainen, Klaus Müller Source Type: research

Infused autograft-absolute lymphocyte count predicts superior survival in Diffuse Large B-Cell Lymphoma patients post-autologous peripheral blood hematopoietic stem cell transplantation: a matched-control study
Day 15 absolute lymphocyte count (ALC-15) recovery after autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) is recognized as a prognostic factor for survival [1-3]. ALC-15 recovery is directly dependent on the amount of collected and infused autograft-absolute lymphocyte count (A-ALC) [4-5]. Retrospective studies have reported that the A-ALC is also a prognostic factor for clinical outcomes post-APBHSCT [4-6]. Our group published a double-blind phase III study showing that patients infused with an A-ALC ≥ 0.5 × 109 cells/kg compared with patients infused with an A-ALC (Source: Biolog...
Source: Biology of Blood and Marrow Transplantation - June 2, 2021 Category: Hematology Authors: Luis F. Porrata, Edwin A. Burglaster, Jeffrey L. Winters, Eapen Jacob, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Jose Villasboas, Jonas Paludo, Svetomir N. Markovic Source Type: research

A Timely CIBMTR Analysis of How Cryopreservation Impacts Allogeneic Hematopoietic Cell Transplantation to Apply in the COVID Era
At several critical stages of the COVID-19 pandemic, transplant centres have embraced the practice of universal cryopreservation of unrelated allogeneic stem cell products. Cryopreservation of products prior to initiating the conditioning regimen provides assurance that the product is available before committing patients to high dose chemotherapy and immune suppression. Indeed, it remains astounding that collecting cells from allogeneic donors, whether related or unrelated, and whether from down the road or across the world, remains feasible at all given issues with stay-at-home orders, international and regional travel re...
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Authors: David S. Allan Tags: The Bottom Line Source Type: research

Selection of Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplasia - New Evidence Emerges
Allogeneic hematopoietic stem cell transplantation (allo-SCT) continues to represent the optimal curative treatment strategy in adults with high risk acute myeloid leukemia (AML) or myelodysplasia (MDS). The combination of dose intensification delivered by the conditioning regimen and a potent graft-versus-leukemia effect substantially reduces the risk of disease relapse compared with intensive chemotherapy alone.1,2 However the therapeutic benefit of allo-SCT remains blunted by the toxicity of transplantation -particularly in recipients of myeloablative conditioning (MAC) regimens. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Authors: Sylvie D Freeman, Charles Craddock Tags: The Bottom Line Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Source Type: research

ASTCT Notes
The Fall Clinical Education Virtual Conference is a multi-day conference for APPs, Nurses, Fellows and Junior Faculty that focuses on the care of blood and marrow transplant and cell therapy patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - June 1, 2021 Category: Hematology Source Type: research

Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant
Post-transplantation cyclophosphamide (PTCy) has emerged as a promising graft-versus-host-disease (GVHD) prophylaxis in the setting of allogeneic hematopoietic stem cell transplantation (HSCT) from haploidentical donors and more recently in matched donor transplants. Herein, we describe our real-life experience on 249 adult patients undergoing allogeneic HSCT, from HLA-matched related (MRD), HLA-matched unrelated (MUD), or mismatched related donors (MMRD). Patients received unmanipulated peripheral blood stem cells (PBSCs), using a GVHD prophylaxis with PTCy and sirolimus. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 31, 2021 Category: Hematology Authors: Raffaella Greco, Francesca Lorentino, Serena Albanese, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Daniela Clerici, Lorenzo Lazzari, Magda Marcatti, Sara Mastaglio, Elisabetta Xue, Francesca Farina, Francesca Pavesi, Andrea Assanelli, Tags: ARTICLE Source Type: research

Post-Transplant Cyclophosphamide and Sirolimus based Graft-versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for many patients with high-risk hematological malignancies.1, 2 Although the outcome of allogeneic HSCT has dramatically improved over the past decade and despite its therapeutic potential,3 toxicities following its application and transplant-related mortality (TRM) still limit its use. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 31, 2021 Category: Hematology Authors: Raffaella Greco, Francesca Lorentino, Serena Albanese, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Daniela Clerici, Lorenzo Lazzari, Magda Marcatti, Sara Mastaglio, Elisabetta Xue, Francesca Farina, Francesca Pavesi, Andrea Assanelli, Source Type: research

Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients
Elderly patients with acute myeloid leukemia (eAML), usually defined as aged 60 years and older, have different biology with more frequent unfavorable cytogenetics, a decline in performance status, or acquired comorbidities, resulting in increased non-relapse mortality (NRM) and relapse than in younger patients with acute myeloid leukemia (AML) [1]. The chemotherapy-only approach in eAML was shown to result in poor survival outcomes due to the high relapse rate [2,3], and primary and secondary drug resistance remain major clinical challenges for most patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 31, 2021 Category: Hematology Authors: Byung-Sik Cho, Seung-Ah Yahng, Gi-June Min, Silvia Park, Sung-Soo Park, Seung-Hwan Shin, Young-Woo Jeon, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Myungshin Kim, Yonggoo Kim, Source Type: research

Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pre-Transplantation Variables and Correlation with Post-Transplant Outcomes
Allogeneic hematopoietic stem cell transplant (HSCT) remains one of the curative therapies for malignant and non-malignant hematologic and immune disorders.1 Long-term outcome of HSCT depends on several variables including age, disease, conditioning regimen, type of graft, graft manipulation, and graft-versus-host disease (GvHD) prophylaxis. Given recent advances in laboratory methodology, we can now study donor-host chimerism post-HCST in more detail by analyzing donor-host percentages for different hematopoietic lineages.   Despite increased knowledge on donor-host chimerism status post-HSCT, its impact remains poor...
Source: Biology of Blood and Marrow Transplantation - May 30, 2021 Category: Hematology Authors: Gabriela Llaurador, Eileen Nicoletti, Susan E Prockop, Susan Hsu, Kirsten Fuller, Audrey Mauguen, Gabriela O'Reilly, Jaap J Boelens, Farid Boulad Source Type: research

Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products
Peripheral blood, marrow and cord blood are potential sources of hematopoietic stem cells for an allogeneic hematopoietic stem cell transplantation (alloHSCT). The choice of source depends on various factors such as recipient age and their underlying condition, weight mismatch between donor-recipient pairs, type of donor, age of donor, and conditioning therapy. While G-CSF mobilized peripheral blood allografts have become the most commonly used source for alloHSCT, the rapid rise of haploidentical transplants as well as registry studies reporting superior long term graft versus host disease (GVHD) relapse free survival (GR...
Source: Biology of Blood and Marrow Transplantation - May 30, 2021 Category: Hematology Authors: Brennan Parmelee Streck, Georges Naufal, George Carrum, LaQuisa Hill, Helen E. Heslop, Carlos A. Ramos, Rammurti Kamble, Marsha Cohen, Kimberly East, Maria Sena, Premal Lulla Source Type: research

Late-onset Acute and Chronic Graft-Versus-Host Disease in Children: Clinical features and Response to Therapy
Long-term morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT) can result from late acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). Late aGVHD is defined as aGVHD present or developing after day 100 without chronic GVHD and is classified into de novo, persistent, and recurrent late aGVHD according to its onset1,2. Although cGVHD presents at any time after an allogeneic HCT with variable systemic symptoms, the majority of the cases occur after day 100 3. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 30, 2021 Category: Hematology Authors: Takuto Takahashi, Mukta Arora, GrigoriOkoev, Todd E. DeFor, Daniel J. Weisdorf, Margaret L. MacMillan Source Type: research

Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma
Autologous CD19-targeted chimeric antigen receptor (CAR) T cell therapy has demonstrated the ability to produce durable remissions in patients with relapsed or refractory large B cell lymphoma (LBCL). There are currently 3 commercially available CAR T products for LBCL: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and the recently approved lisocabtagene maraleucel [1-3]. In the pivotal ZUMA-1 trial of axi-cel, 83% of patients had an objective response, and 39% had an ongoing response at a median follow-up of 27.1 months [4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 29, 2021 Category: Hematology Authors: Albert Cortes, Ariel Perez, Christina Bachmeier, Rahul Mhaskar, Julio C. Chavez, Bijal Shah, Taiga Nishihori, Farhad Khimani, Aleksandr Lazaryan, Marco L. Davila, Frederick L. Locke, Michael D. Jain Source Type: research

Outcomes of CD19 CAR T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma
Autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy has demonstrated the ability to produce durable remissions in patients with relapsed or refractory large B cell lymphoma (LBCL). There are currently three commercially available CAR T products for LBCL, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), with the third product, lisocabtagene maraleucel, recently approved.1-3 In the pivotal ZUMA-1 trial for axi-cel, 83% of patients had an objective response, with 39% of patients with ongoing response at a median follow up of 27.1 months. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 29, 2021 Category: Hematology Authors: Albert Cortes, Ariel Perez, Christina Bachmeier, Rahul Mhaskar, Julio C. Chavez, Bijal Shah, Taiga Nishihori, Farhad Khimani, Aleksandr Lazaryan, Marco L. Davila, Frederick L. Locke, Michael D. Jain Source Type: research

Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric PAH and PVOD after HSCT
Pulmonary hypertension (PH) is characterized by increased pulmonary vascular resistance and elevated right ventricular pressure, which is not a common complication of hematopoietic stem cell transplantation (HSCT). Patients with PH are occasionally asymptomatic in the early stage, leading to a delay in obtaining an accurate diagnosis1, 2. Moreover, those with advanced-stage PH are at high risk of sudden cardiac death. Targeted combination therapies with phosphodiesterase-5 inhibitors, endothelial receptor antagonists, and prostanoids have remarkably improved outcomes in patients with PH3. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 28, 2021 Category: Hematology Authors: Nozomu Kawashima, Yoshie Fukasawa, Eri Nishikawa, Keiko Ohta-Ogo, Hatsue Ishibashi-Ueda, Motoharu Hamada, Daisuke Ichikawa, Atsushi Narita, Yusuke Okuno, Hideki Muramatsu, Nobuhiro Nishio, Seiji Kojima, Taichi Kato, Yoshiyuki Takahashi Source Type: research

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis —A Systematic Review and Meta-Analysis
Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative therapeutic modality for patients with primary or secondary myelofibrosis (MF). However, many patients are considered ineligible for allo-HCT, and transplant-related mortality can be substantial. Data on the efficacy and safety of allo-HCT are mixed and largely derived from retrospective studies. We wanted to synthesize the available evidence on the safety and efficacy of allo-HCT in MF and to identify patient, disease, and transplant characteristics with prognostic impact on outcomes of patients with MF undergoing allo-HCT. (Source: ...
Source: Biology of Blood and Marrow Transplantation - May 27, 2021 Category: Hematology Authors: Jan Philipp Bewersdorf, Amar H. Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Roni Tamari, Martin S. Tallman, Raajit K. Rampal, Amer M. Zeidan, Maximilian Stahl Source Type: research

Hepatitis B seropositive status in recipients or donors is not related to worse outcomes after haploidentical hematopoietic stem cell transplantation
Hepatitis B virus (HBV) has a high chronic infection rate in Asian population and limited studies are performed to analyze the impact of HBV seropositive recipients or donors in the condition of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 27, 2021 Category: Hematology Authors: Chunzi Yu, Yuqian Sun, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Jian Jin, Xiaojun Huang, Yu Wang Source Type: research

Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis – a systematic review and meta-analysis
Together with essential thrombocythemia (ET) and polycythemia vera (PV), primary myelofibrosis (MF) belongs to the heterogenous group of BCR-ABL1-negative myeloproliferative neoplasms (MPN). While the prognosis for individual patients is variable, MF has been associated with inferior survival compared to both healthy, age-matched controls and patients with PV and ET.1, 2 Registry data from the United States reported a median age of diagnosis for primary MF of 69 years and a median overall survival (OS) of 3.6 years. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 27, 2021 Category: Hematology Authors: Jan Philipp Bewersdorf, Amar H. Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Roni Tamari, Martin S. Tallman, Raajit K. Rampal, Amer M. Zeidan, Maximilian Stahl Source Type: research

Attitudes about Donating Stem Cells during COVID-19 among African American and Hispanic Members of an Unrelated Donor Registry
The use of unrelated hematopoietic stem cell (HSC) donors as a source of stem cells for patients ill with blood-related disorders continues to increase. Younger potential unrelated hematopoietic stem cell (HSC) donors aged 18-30 are both the most clinically desirable and least available to donate after having preliminarily matched a patient in need of a transplant.1 –6 Among this group, ethnic minority potential donors (particularly African Americans and Hispanics) are further underrepresented on the National Marrow Donor Program (NMDP) registry and are more likely to opt-out after matching a patient than their count...
Source: Biology of Blood and Marrow Transplantation - May 24, 2021 Category: Hematology Authors: Galen E. Switzer, Megan E. Hamm, Jessica G. Bruce, Alicia Dawdani, Vidya Kuniyil, Deborah Mattila, Eric P. Williams, Mary Amanda Dew, Larissa Myaskovsky, Linda K. Abress, Dennis L. Confer Source Type: research

Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy
Reduced-intensity conditioning (RIC) regimens have expanded hematopoietic cell transplantation (HCT) indications to high-risk patients who were otherwise ineligible for myeloablative regimens because of older age, extensive prior therapy, or comorbidities. RIC regimens aim to be immunoablative with limited organ and systemic toxic effects while still enabling the graft antitumor effects [1]. Fludarabine (Flu) and cyclophosphamide (Cy) have been widely used in RIC regimens, but the association between their systemic exposures and HCT outcomes are not well understood. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 23, 2021 Category: Hematology Authors: Takuto Takahashi, Aileen Scheibner, Qing Cao, Rachael Pearson, Kinjal Sanghavi, Daniel J. Weisdorf, Claudio G. Brunstein, John Rogosheske, Veronika Bachanova, Erica D. Warlick, Anthony Wiseman, Pamala A. Jacobson Source Type: research

Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Hematopoietic Cell Transplantation for Adult Hematologic Malignancy
Reduced-intensity conditioning (RIC) regimens have expanded hematopoietic cell transplantation (HCT) indications to high-risk patients who were otherwise ineligible for myeloablative regimens because of older age, extensive prior therapy, or comorbidities. RIC regimens aim to be immunoablative with limited organ and systemic toxic effects while still enabling the graft antitumor effects [1]. Fludarabine (Flu) and cyclophosphamide (Cy) have been widely used in RIC regimens, but the association between their systemic exposures and HCT outcomes are not well understood. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 23, 2021 Category: Hematology Authors: Takuto Takahashi, Aileen Scheibner, Qing Cao, Rachael Pearson, Kinjal Sanghavi, Daniel Weisdorf, Claudio Brunstein, John Rogosheske, Veronika Bachanova, Erica D. Warlick, Anthony Wiseman, Pamala A. Jacobson Source Type: research

Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced Intensity Hematopoietic Cell Transplant for Adult Hematologic Malignancy
Reduced intensity conditioning (RIC) regimens have expanded hematopoietic cell transplantation (HCT) indications to high-risk patients who were otherwise not eligible for myeloablative regimens because of older age, extensive prior therapy, or comorbidities. RIC regimens aim to be immunoablative with limited organ and systemic toxic effects, yet enabling the graft anti-tumor effects1. Fludarabine (FLU) and cyclophosphamide (CY) have been widely used in RIC regimens, but the association between their systemic exposures and HCT outcomes are not well understood. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 23, 2021 Category: Hematology Authors: Takuto Takahashi, Aileen Scheibner, Qing Cao, Rachael Pearson, Kinjal Sanghavi, Daniel Weisdorf, Claudio Brunstein, John Rogosheske, Veronika Bachanova, Erica D. Warlick, Anthony Wiseman, Pamala A. Jacobson Source Type: research

Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) are among the most frequent indications for allogeneic hematopoietic cell transplantation (allo-HCT). Allo-HCT represents the sole option with curative potential for many patients and is standard of care for fit patients with high-risk disease features. Survival at 3 years after allo-HCT is between 50% and 60% for patients with AML in remission, approximately 30% for patients with relapsed/refractory AML, and between 45% and 55% for patients with MDS [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 22, 2021 Category: Hematology Authors: Corrado Zuanelli Brambilla, Stephanie M. Lobaugh, Josel D. Ruiz, Parastoo B. Dahi, Aaron D. Goldberg, James W. Young, Boglarka Gyurkocza, Brian C. Shaffer, Doris M. Ponce, Roni Tamari, Miriam Sanchez Escamilla, Nerea Castillo Flores, Ioannis Politikos, Mi Source Type: research

Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are among the most frequent indications for allogeneic hematopoietic cell transplantation (alloHCT). AlloHCT represents the only option with curative potential for many patients and is standard of care for fit patients with high-risk disease features. Survival 3 years after alloHCT is between 50 to 60% for patients with AML in remission, around 30% for patients with relapsed/refractory AML, and between 45 to 55% for patients with MDS1. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 22, 2021 Category: Hematology Authors: Corrado Zuanelli Brambilla, Stephanie M. Lobaugh, Josel D. Ruiz, Parastoo B. Dahi, Aaron D. Goldberg, James W. Young, Boglarka Gyurkocza, Brian C. Shaffer, Doris M. Ponce, Roni Tamari, Miriam Sanchez Escamilla, Nerea Castillo Flores, Ioannis Politikos, Mi Source Type: research